Japan MHLW Insurance Coverage Consultation: What Healthcare Companies Should Prepare

Japan’s Ministry of Health, Labour and Welfare is holding consultation meetings for companies and research organizations seeking guidance on insurance coverage for drugs, medical devices, and in-vitro diagnostics.

The Kyoto session was held on October 2, 2026. The Fukuoka session is scheduled for November 24, 2026 and is limited to medical devices and in-vitro diagnostic products. The consultation application deadline is November 4, 2026.

Why the meeting matters

The consultation provides an opportunity to clarify how a product may be evaluated for insurance coverage before a company spends more time and resources on the wrong development or evidence path.

Prepare a focused question

The available slots are limited. A useful consultation starts with one or two clearly defined questions rather than a broad presentation. The company should identify the decision it needs to make after the meeting.

Bring the right evidence

Participants should prepare a concise description of the product, intended use, development stage, available clinical evidence, and the specific insurance-coverage issue that needs clarification.

Coordinate with other regulatory steps

Insurance coverage is only one part of the development pathway. Companies should also consider how the discussion relates to PMDA consultation, clinical evidence generation, and commercialization planning.

Practical takeaway

The value of the meeting depends on preparation. A short, decision-oriented briefing is more useful than a long overview with no clear question.